Over the last four decades, pharmaceutical companies' expenditures on research and development have increased 51-fold. During this same time, clinical success rates for new drugs have remained unchanged at about 10 percent, predominantly due to lack of efficacy and/or safety concerns. This persistent problem underscores the need to innovate across the entire drug development process, particularly in drug formulation, which is often deprioritized and under-resourced.
Keywords: AI; drug development; drug formulation; machine learning; robotics.
© 2024 The Author(s). Advanced Healthcare Materials published by Wiley‐VCH GmbH.